Drug-Induced Liver Injury: Biomarkers, Requirements, Candidates, and Validation

Front Pharmacol. 2019 Dec 11;10:1482. doi: 10.3389/fphar.2019.01482. eCollection 2019.


The hepatotoxicity of drugs is the main cause of drug withdrawal from the pharmaceutical market and interruption of the development of new molecules. Biomarkers are useful in several situations. In case of suspected drug-induced liver injury (DILI), biomarkers can be used to confirm liver damage, its severity, prognosis, confirm drug causality, or define the type of DILI. In this review, we will first present the currently used biomarkers and candidate biomarkers for the future. The current biomarkers are certainly very helpful including with the assistance of diagnostic method such the Roussel Uclaf Causality Assessment Method, but provide a limited information for the early detection of liver injury, the role of specific drug and the prediction of DILI. Some biomarkers are promising but they are not yet available for routine use. Studies are still needed to confirm their interest, particularly in comparison to Roussel Uclaf Causality Assessment Method.

Keywords: RUCAM; biomarkers; drug-induced liver injury; hepatotoxicity; novel candidate.

Publication types

  • Review